In this study no conclusions regarding efficacy in terms of spirometric parameters can be deduced because these were only measured 24 hours after washout of salmeterol, before nebulised salbutamol. Thus, to make a statement that bronchodilator efficacy in COPD should be assessed from daily peak flow recordings is not based on sound methodology, at least from this study. It was also hardly surprising that it was not possible to detect any diminution in response to nebulised salbutamol, given that the response signal was of such small magnitude.
In this respect we have shown that chronic dosing with salmeterol in COPD had a mean effet on FEV, of 0-11 litres compared with placebo, and was not associated with any improvement in walking distance or exercise parameters. 
